Valion Bio, Inc. Operating Lease, Payments
Valion Bio, Inc. (VBIO) reported Operating Lease, Payments of $375.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-05-14
- Valion Bio, Inc. operating lease, payments for the quarter ending 2026-03-31 was $375.00K.
- Valion Bio, Inc. operating lease, payments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Valion Bio, Inc. operating lease, payments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Valion Bio, Inc. operating lease, payments for the quarter ending 2024-06-30 was $34.00K, a 34.62% decline year-over-year.
- Valion Bio, Inc. operating lease, payments for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Valion Bio, Inc. operating lease, payments for fiscal 2024 was $87.00K, a 57.77% decline from fiscal 2023.
- Valion Bio, Inc. operating lease, payments for fiscal 2023 was $206.00K, a 8.99% increase from fiscal 2022.
- Valion Bio, Inc. operating lease, payments for fiscal 2022 was $189.00K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | $375.00K 10-Q · filed 2026-05-14 | |||||
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $34.00K derived: sum of 3 quarters · filed 2026-03-30 | $87.00K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | $34.00K derived: sum of 2 quarters · filed 2024-11-14 | $87.00K 10-Q · filed 2024-11-14 | $137.00K derived: sum of 4 quarters · filed 2025-03-21 | ||
| 2024-06-30 | $34.00K 10-Q · filed 2024-08-14 | $87.00K 10-Q · filed 2024-08-14 | $137.00K derived: sum of 3 quarters · filed 2025-03-21 | $188.00K derived: sum of 4 quarters · filed 2025-03-21 | ||
| 2024-03-31 | $51.00K 10-Q · filed 2024-05-15 | $103.00K derived: sum of 2 quarters · filed 2025-03-21 | $154.00K derived: sum of 3 quarters · filed 2025-03-21 | $206.00K derived: sum of 4 quarters · filed 2025-03-21 | ||
| 2023-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $103.00K derived: sum of 2 quarters · filed 2025-03-21 | $155.00K derived: sum of 3 quarters · filed 2025-03-21 | $206.00K 10-K · filed 2025-03-21 | ||
| 2023-09-30 | $51.00K 10-Q · filed 2024-11-14 | $103.00K derived: sum of 2 quarters · filed 2024-11-14 | $154.00K 10-Q · filed 2024-11-14 | $204.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $52.00K 10-Q · filed 2024-08-14 | $103.00K 10-Q · filed 2024-08-14 | $153.00K derived: sum of 3 quarters · filed 2024-08-14 | $203.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $50.00K 10-Q · filed 2024-05-15 | $51.00K 10-Q · filed 2023-05-15 | $101.00K derived: sum of 2 quarters · filed 2024-05-15 | $151.00K derived: sum of 3 quarters · filed 2024-05-15 | $201.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $101.00K derived: sum of 2 quarters · filed 2024-03-25 | $151.00K derived: sum of 3 quarters · filed 2024-03-25 | $189.00K 10-K · filed 2024-03-25 | $189.00 10-K · filed 2023-03-31 | |
| 2022-09-30 | $50.00K 10-Q · filed 2023-11-14 | $100.00K derived: sum of 2 quarters · filed 2023-11-14 | $138.00K 10-Q · filed 2023-11-14 | $146.00K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $50.00K 10-Q · filed 2023-08-14 | $88.00K 10-Q · filed 2023-08-14 | $96.00K derived: sum of 3 quarters · filed 2023-08-14 | $96.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $46.00K 10-Q · filed 2023-05-15 | $46.00K derived: sum of 2 quarters · filed 2023-05-15 | $46.00K derived: sum of 3 quarters · filed 2023-05-15 | $46.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |